Presentation is loading. Please wait.

Presentation is loading. Please wait.

Cost-Effectiveness and Cost-Utility Analyses of Dabigatran Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation and Risk Factors for.

Similar presentations


Presentation on theme: "Cost-Effectiveness and Cost-Utility Analyses of Dabigatran Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation and Risk Factors for."— Presentation transcript:

1 Cost-Effectiveness and Cost-Utility Analyses of Dabigatran Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation and Risk Factors for Stroke and Systemic Embolism within Brazilian Private and Public Health Care Systems Perspectives  Camila Pepe Ribeiro de Souza, MsC, Natália Bolzachini Santoni, BsC, Thais Gomes de Melo, MsC, Marcio Jansen de Oliveira Figueiredo, PhD, Francisco Carlos da Costa Darrieux, PhD, Leopoldo Soares Piegas, PhD, Sheila Ouriques Martins, PhD  Value in Health Regional Issues  Volume 8, Pages (December 2015) DOI: /j.vhri Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2 Fig. 1 Markov model structure.
Value in Health Regional Issues 2015 8, 36-42DOI: ( /j.vhri ) Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions


Download ppt "Cost-Effectiveness and Cost-Utility Analyses of Dabigatran Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation and Risk Factors for."

Similar presentations


Ads by Google